Hongguang Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hongguang Zhu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bingqing Zou
Department of Pathology, Fudan University Shanghai Medical College, Shanghai, 200030, China
1 shared publication Hai Feng Zhou
Department of Implant Alveolar Surgery, Weifang People's Hospital, Shandong Second Medical University, China
1 shared publicationHaifeng Zhou
Department of Stomatology, Weifang People’s Hospital, Weifang, Shandong, China
1 shared publicationHong-Lin Yin
Department of Pathology, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China
1 shared publicationHuan Li
Department of Implant Alveolar Surgery, Weifang People's Hospital, Shandong Second Medical University, China
1 shared publication- Hui Guo
Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China
1 shared publication
Latest Publications
- Open Access
- 24 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (30) , e49851
Exploring the potential causal relationship between lipid metabolism and oral carcinoma in situ: A 2-sample Mendelian randomization study
Oral carcinoma in situ (OCIS) is a Stage 0 precancerous condition with a significant risk of developing into invasive oral squamous cell carcinoma. Despite this, the metabolic processes driving its onset and progression remain largely unknown. Lipid metabolism, a crucial factor in the development and behavior of various cancers, has been extensively studied. However, its exact role in OCIS has not been clearly defined, highlighting the need for further research in this area. The present study is designed to investigate the potential causal associations between specific lipid metabolic markers and OCIS through the application of Mendelian randomization (MR) analysis. Our statistical analyses indicated nominal positive correlations between 2 lipid metabolic markers and the risk of OCIS. Specifically, polyunsaturated fatty acids and total cholesterol levels in very large high-density lipoprotein were associated with increased OCIS risk, with odds ratios of 2.32 (nominal P value = .0463) and 2.43 (nominal P value = .0439) per 1 standard deviation in this marker, respectively. Conversely, the phospholipid-to-total lipid ratio in small very low-density lipoprotein showed a nominal inverse association with OCIS risk, with an odds ratio of 0.31 (nominal P value = .0408) per 1 standard deviation in this marker. False discovery rate correction was applied for multiple testing, and no associations reached study-wide significance. Subsequent sensitivity analyses confirmed the robustness of these nominal findings, and no substantial evidence of horizontal pleiotropy was detected for 3 of the lipid metabolic marker-OCIS associations. This exploratory study identifies 3 lipid metabolic markers (polyunsaturated fatty acids, total cholesterol levels in very large high-density lipoprotein, the phospholipid-to-total lipid ratio in small very low-density lipoprotein) that are consistent with a possible nominal effect on OCIS risk. Summary-level genome-wide association study data were used for exposures (233 lipid metabolic markers, 136,016 European-ancestry participants, genome-wide association study Catalog accession numbers GCST90301941-GCST90302173) and outcome (OCIS, 71 cases and 378,725 controls of European-ancestry participants from the FinnGen project, release version R12, data accessed in November 2024). Instrumental variables were selected based on genome-wide significance ( P < 5 × 10 −8 ), linkage disequilibrium ( R 2 < 0.001, 10,000 kb window), and F -statistic > 10. The primary MR analysis used the inverse-variance weighted method. Sensitivity analyses included MR-Egger regression, weighted median, MR-Pleiotropy RESidual Sum and Outlier, and leave-one-out tests.
- 24 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (30) , e49851
Open AccessExploring the potential causal relationship between lipid metabolism and oral carcinoma in situ: A 2-sample Mendelian randomization study
Oral carcinoma in situ (OCIS) is a Stage 0 precancerous condition with a significant risk of developing into invasive oral squamous cell carcinoma. Despite this, the metabolic processes driving its onset and progression remain largely unknown. Lipid metabolism, a crucial factor in the development and behavior of various cancers, has been extensively studied. However, its exact role in OCIS has not been clearly defined, highlighting the need for further research in this area. The present study is designed to investigate the potential causal associations between specific lipid metabolic markers and OCIS through the application of Mendelian randomization (MR) analysis. Our statistical analyses indicated nominal positive correlations between 2 lipid metabolic markers and the risk of OCIS. Specifically, polyunsaturated fatty acids and total cholesterol levels in very large high-density lipoprotein were associated with increased OCIS risk, with odds ratios of 2.32 (nominal P value = .0463) and 2.43 (nominal P value = .0439) per 1 standard deviation in this marker, respectively. Conversely, the phospholipid-to-total lipid ratio in small very low-density lipoprotein showed a nominal inverse association with OCIS risk, with an odds ratio of 0.31 (nominal P value = .0408) per 1 standard deviation in this marker. False discovery rate correction was applied for multiple testing, and no associations reached study-wide significance. Subsequent sensitivity analyses confirmed the robustness of these nominal findings, and no substantial evidence of horizontal pleiotropy was detected for 3 of the lipid metabolic marker-OCIS associations. This exploratory study identifies 3 lipid metabolic markers (polyunsaturated fatty acids, total cholesterol levels in very large high-density lipoprotein, the phospholipid-to-total lipid ratio in small very low-density lipoprotein) that are consistent with a possible nominal effect on OCIS risk. Summary-level genome-wide association study data were used for exposures (233 lipid metabolic markers, 136,016 European-ancestry participants, genome-wide association study Catalog accession numbers GCST90301941-GCST90302173) and outcome (OCIS, 71 cases and 378,725 controls of European-ancestry participants from the FinnGen project, release version R12, data accessed in November 2024). Instrumental variables were selected based on genome-wide significance ( P < 5 × 10 −8 ), linkage disequilibrium ( R 2 < 0.001, 10,000 kb window), and F -statistic > 10. The primary MR analysis used the inverse-variance weighted method. Sensitivity analyses included MR-Egger regression, weighted median, MR-Pleiotropy RESidual Sum and Outlier, and leave-one-out tests.
- 12 February 2026
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 94, 127839
Titanium ion inhibits osteogenic ability of osteoblasts by up-regulating osteoblast Agt gene via macrophages
- 12 February 2026
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 94, 127839
Titanium ion inhibits osteogenic ability of osteoblasts by up-regulating osteoblast Agt gene via macrophages
- 1 October 2016
- Published by Elsevier in Human Pathology
- Vol. 56, 114-122
Clonal and genetic relationship between individual components of mucoepidermoid carcinoma: X-chromosome inactivation assay and microsatellite analysis
- 1 October 2016
- Published by Elsevier in Human Pathology
- Vol. 56, 114-122
Clonal and genetic relationship between individual components of mucoepidermoid carcinoma: X-chromosome inactivation assay and microsatellite analysis
- Open Access
- 1 January 2013
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 9 (3) , 303-312
Development of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma
Background & Aims: Adjuvant therapies for hepatocellular carcinoma (HCC) such as interferon-alpha are effective only in a subset of patients. Previously we found that HCC patients with low level of miR-26 have survival benefits from interferon-alpha. The purpose of this study is to develop a standardized miR-26 diagnostic test (referred as MIR26-DX) to assist identification of candidate HCC patients for adjuvant interferon-alpha therapy.
- 1 January 2013
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 9 (3) , 303-312
Open AccessDevelopment of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma
Background & Aims: Adjuvant therapies for hepatocellular carcinoma (HCC) such as interferon-alpha are effective only in a subset of patients. Previously we found that HCC patients with low level of miR-26 have survival benefits from interferon-alpha. The purpose of this study is to develop a standardized miR-26 diagnostic test (referred as MIR26-DX) to assist identification of candidate HCC patients for adjuvant interferon-alpha therapy.
- Open Access
- 1 September 2012
- Vol. 1 (1) , 15-12
Expert consensus on the scheme of pathological diagnosis of primary liver cancer
- 1 September 2012
- Vol. 1 (1) , 15-12
Open AccessExpert consensus on the scheme of pathological diagnosis of primary liver cancer